The Organic Chemistry of Drug Synthesis, Volume 3 - (Organic Chemistry Drug Synthesis) by Daniel Lednicer & Lester A Mitscher (Hardcover)

Book Synopsis

Dieser Band befa't sich mit der Entwicklung von RU 486 (Mifapriston), Taxol und 12 anderen, neu entwickelten Medikamenten.

Neben der Beschreibung einzelner Arzneimittel werden auch Anwendungsmoglichkeiten aufgezahlt.

Die Erfinder dieser Medikamente beschreiben daruber hinaus samtliche Schritte von der Entdeckung bis hin zur Einfuhrung im Handel, sowie Probleme, die vor der endgultigen Zulassung der Medikamente bei zustandigen Behorden auftraten.

From the Back Cover

The classic reference on the synthesis of medicinal agents --now completely updated

The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classesof therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6.Many of these compounds represent novel structural types firstidentified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered.

As in the previous volumes, materials are organized by chemical class and syntheses originate with available starting materials. Organized to make the information accessible, this resource covers disease state, rationale for method of drug therapy, and the biological activities of each compound and preparation. The Organic Chemistry of Drug Synthesis, Volume 7 is a hands-on reference for medicinal and organic chemists, and a great resource for graduate and advanced undergraduate students in organic and medicinal chemistry.

Review Quotes

"The book is up-to-date with regard to the drugs presented and has the potential to be a good resources for experienced researchers in drug design..." ("Journal of the American Chemical Society", March 12, 2008)

About the Author

Daniel Lednicer, PhD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.

Lester A. Mitscher, Ph.D., recognized for his research achievements by numerous institutions, serves as a consultant for the National Institutes of Health, among other organizations. Dr. Mitscher is a professor at the University of Kansas and the Victorian College of Pharmacy at Monash University outside Melbourne, Australia. Victoria Dolby Toews, MPH, a veteran freelance researcher and writer, has written and coauthored many books on health and wellness. She lives in the Pacific Northwest.